AI assistant
MEMPHASYS LIMITED. — Capital/Financing Update 2020
Oct 27, 2020
65314_rns_2020-10-27_d4e99aa5-35cf-4798-944e-8cdc3484a0d4.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
ASX Release 28 October 2020
ASX Code: MEM
==> picture [222 x 64] intentionally omitted <==
Reinstatement of Options
Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) wishes to advise that 366,548 unlisted options granted to former non-executive director, Marjan Mikel, were erroneously cancelled on 30 June 2020.
The ASX Annnouncement of 3 July 2020 reported the cancellation of 2,199,292 unlisted options instead of the correct amount of 1,832,744. The options were awarded in lieu of director fees to executive director, Marjan Mikel, to acquire fully paid shares exercisable at $0.1142 on or before 22 October 2021.
Upon Marjan Mikel’s resignation from the board on 21 February 2020, a cumulative total of 366,548 of the 1,099,646 options granted to him were vested and therefore should not have been cancelled.
The error has now been rectified and the 366,548 unlisted options to Marjan Mickel are now reinstated on the Company’s register.
| Memphasys Limited - Issued capital to 28 October 2020 | Issued Securities |
|---|---|
| (after error correction) | |
| Description | |
| Director Options $0.1142 Exp 22 October 2021 | 1,466,194 |
| Employee & Consultant Options $0.1142 Exp 22 Oct 2021 | 7,550,000 |
| Fully Paid Ordinary Shares | 754,773,880 |
| Goodall Options $0.1142 Exp 22 October 2021 | 989,681 |
| Incentive Options $0.1142 Exp 22 October 2021 | 18,000,000 |
| Unlisted Options $0.0332 exp 28/09/2021 | 20,000,000 |
| Unlisted Options $0.0332 exp 28/09/2021 | 17,404,457 |
This announcement has been approved for release by Alison Coutts, Executive Chair of Memphasys Limited.
ENDS
For further information please contact:
Alison Coutts Andrew Metcalfe Executive Chairman Company Secretary Memphasys Limited Memphasys Limited T: +61 2 8415 7300 T: +0412 125 090 E:[email protected] E: [email protected]
About Memphasys:
Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained. The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.
Website: www.memphasys.com